Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kelvin K W Chan

Showing results (1-10 of 234) with videos related to

Pageof 24
Sort By:
BMJ (Clinical Research Ed.)|November 5, 2020
Prioritising research into cancer treatment delaysAmbica Parmar, Kelvin K W Chan
Cancer|May 25, 2011
Risk of mortality in patients with cancer who experience febrile neutropeniaKelvin K W Chan, George Tomlinson
Nature Reviews. Urology|November 8, 2019
Health technology assessment methodology in metastatic renal cell carcinomaAmbica Parmar, Kelvin K W Chan
International Journal of Cancer|May 5, 2021
The impact of socioeconomic status on stage at presentation, receipt of diagnostic imaging, receipt of treatment and overall survival in colorectal cancer patientsRajan Shah, Kelvin K W Chan
Medical Decision Making : an International Journal of the Society for Medical Decision Making|May 20, 2020
The Theoretical Relationship between Sample Size and Expected Predictive Precision for EQ-5D Valuation Studies: A Mathematical Exploration and Simulation StudyKelvin K W Chan, Eleanor M Pullenayegum
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 12, 2021
Should Basket Trials Be Pathways to Drug Registration for Biomarker-Defined Subgroups of Advanced Cancers?Kelvin K-W Chan, Ian F Tannock
European Journal of Cancer (Oxford, England : 1990)|December 30, 2015
Is there any benefit to adding adjuvant chemotherapy after concurrent chemoradiotherapy for nasopharyngeal carcinoma?Marie Yan, Alexander Kumachev, Kelvin K W Chan
JAMA Network Open|July 11, 2019
Comparison of Long-term Survival Benefits in Trials of Immune Checkpoint Inhibitor vs Non-Immune Checkpoint Inhibitor Anticancer Agents Using ASCO Value Framework and ESMO Magnitude of Clinical Benefit ScaleLouis Everest, Monica Shah, Kelvin K W Chan
Cancer Medicine|March 21, 2020
Socioeconomic disparity trends in diagnostic imaging, treatments, and survival for non-small cell lung cancer 2007-2016Monica Shah, Ambica Parmar, Kelvin K W Chan
JAMA Oncology|October 18, 2019
Correcting the Conclusion in a Study of Frameworks for Measurement of Absolute or Clinical Benefit-In ReplyRonak Saluja, Matthew Cheung, Kelvin K W Chan
Pageof 24

Showing results (1-10 of 234) with videos related to

Sort By:
Pageof 24
BMJ (Clinical Research Ed.)|November 5, 2020
Prioritising research into cancer treatment delaysAmbica Parmar, Kelvin K W Chan
Cancer|May 25, 2011
Risk of mortality in patients with cancer who experience febrile neutropeniaKelvin K W Chan, George Tomlinson
Nature Reviews. Urology|November 8, 2019
Health technology assessment methodology in metastatic renal cell carcinomaAmbica Parmar, Kelvin K W Chan
International Journal of Cancer|May 5, 2021
The impact of socioeconomic status on stage at presentation, receipt of diagnostic imaging, receipt of treatment and overall survival in colorectal cancer patientsRajan Shah, Kelvin K W Chan
Medical Decision Making : an International Journal of the Society for Medical Decision Making|May 20, 2020
The Theoretical Relationship between Sample Size and Expected Predictive Precision for EQ-5D Valuation Studies: A Mathematical Exploration and Simulation StudyKelvin K W Chan, Eleanor M Pullenayegum
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 12, 2021
Should Basket Trials Be Pathways to Drug Registration for Biomarker-Defined Subgroups of Advanced Cancers?Kelvin K-W Chan, Ian F Tannock
European Journal of Cancer (Oxford, England : 1990)|December 30, 2015
Is there any benefit to adding adjuvant chemotherapy after concurrent chemoradiotherapy for nasopharyngeal carcinoma?Marie Yan, Alexander Kumachev, Kelvin K W Chan
JAMA Network Open|July 11, 2019
Comparison of Long-term Survival Benefits in Trials of Immune Checkpoint Inhibitor vs Non-Immune Checkpoint Inhibitor Anticancer Agents Using ASCO Value Framework and ESMO Magnitude of Clinical Benefit ScaleLouis Everest, Monica Shah, Kelvin K W Chan
Cancer Medicine|March 21, 2020
Socioeconomic disparity trends in diagnostic imaging, treatments, and survival for non-small cell lung cancer 2007-2016Monica Shah, Ambica Parmar, Kelvin K W Chan
JAMA Oncology|October 18, 2019
Correcting the Conclusion in a Study of Frameworks for Measurement of Absolute or Clinical Benefit-In ReplyRonak Saluja, Matthew Cheung, Kelvin K W Chan
Pageof 24